Basic Information
BELLUS Health (NASDAQ: BLU, TSX: BLU) is a clinical-stage biotechnology company developing novel therapies for the treatment of chronic cough and other hypersensitization-related disorders. The company's lead product candidate, BLU-5937, is a highly selective P2X3 antagonist being developed for the treatment of chronic cough and chronic pruritus.
BELLUS Health Inc.
Laval,Quebec,Canada
15~50 people
January 01, 2010
webinfo@bellushealth.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios